Aptiv Makes Adaptive Trial Appointments

Aptiv Solutions has made several appointments and promotions to strengthen its focus in providing adaptive clinical trial services. Corey Dunham has been named senior vice president of Global Data Management. Mr. Dunham serves on the technology team responsible for the growth and development of AptivAdvantage™, the company’s integrated technology platform. Mr. Dunham will play a leadership role in helping clients understand the requirements for successful implementation of complex adaptive clinical trials. He previously led Aptiv’s US Data Management team.

Dr. Martin Geueke has been appointed to the newly-created position of senior vice president of Software Development. Dr. Geueke will lead a global team dedicated to the development of new software to support adaptive clinical trial execution, including customized applications to support specific client requirements. Dr. Geueke has more than 16 years of experience in clinical data management, software development and IT. He has spent the past 12 years developing EDC systems. He previously led Aptiv’s European Data Management team.

Christopher Ellis has been named to the newly created position of vice president, Project Management Europe. Mr. Ellis joined Aptiv Solutions with its recent SRA GCD acquisition. Mr. Ellis will lead project management efforts with a focus on practices and methodology for adaptive trial implementation and execution.

Angela Weston has been named senior vice president of Business Development Europe. She and her team will promote and market adaptive clinical trial design services in Europe.

“Having this team in place is critical for Aptiv Solutions to realize its vision of being the market leader in adaptive clinical trial design, simulation and execution.” said Pat Donnelly, chairman and chief executive officer at Aptiv Solutions. “I am pleased to be surrounded with such talented experts who will facilitate the acceptance of adaptive clinical trials into the development process for pharmaceutical, biotechnology and medical device products.”